Analyst Research

Report Title Price
Provider: Pechala's Reports
Provider: Reuters Investment Profile
Provider: Thomson Reuters Stock Report
Provider: ValuEngine, Inc.

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Skystar Bio Pharmaceutical Co gives FY 2014 revenue guidance

Monday, 31 Mar 2014 07:04pm EDT 

Skystar Bio Pharmaceutical Co:Sees 8 pct. to 18 pct. year over year increase in top line revenue for FY 2014 as compared to the prior year.Says the expected FY 2014 revenue range is $46 million to $50 million. 

Company Quote

-0.08 -2.03%
1 May 2015